Rome, December 20 - With a notice posted yesterday on its website, Aifa has made available the data relating to the monitoring of national and regional pharmaceutical expenditure from January to August 2016, conducted on the basis of the agreed expenditure data of OsMed and the Dcr acquired by the Regions.
The breakthrough of both ceilings is confirmed, both that of territorial expenditure, which between pharmacies and direct distribution (without payback and without innovative products) reaches 8,806 million euros, exceeding the programmed limit of 413 million, and that of hospital expenditure, which records a much more substantial surplus, reaching 3,995 million, or a good 1,271 million euros more than planned.
The weight of citizens' participation is also increasing, with an outlay up by 1.3% compared to the first eight months of 2015: citizens have pulled just over a billion out of their pockets, 680 million of which paid for the difference price between generic and branded and the remainder as a fixed ticket on the recipe.
In all Regions, the gross agreed spending that "passes" to the pharmacy continues to fall: from January to August, it amounted to 7,073 million, or 237 million less than in the same period of 2015 (with a percentage loss of -3 ,2%). Excluding the discounts paid by the supply chain and the tickets paid by citizens, expenditure totaled 5,482 million, with a drop of 230 million compared to the previous year (-4%). The number of prescriptions also decreased: 391 million were "sent" to pharmacies, - 2% compared to the previous year.
By contrast, cThe unstoppable march of direct distribution continues, which increased by 23.1% in the first eight months of 2016 compared to the corresponding period of 2015 and came to "disconnect" the tag of 3,685.3 million euro. In 2015, it had been 2,925.
Related news: Monitoring of National and Regional Pharmaceutical Expenditure (12/19/2016)
- extract on the Monitoring of National and Regional Pharmaceutical Expenditure (January / June 2016)
- extract on the Monitoring of National and Regional Pharmaceutical Expenditure (January / July 2016)
- extract on the Monitoring of National and Regional Pharmaceutical Expenditure (January / August 2016)
